BIOMAT Database Logo BIOMAT Database Logo

Exploration of Pyrazolo[1,5-a]pyrimidines as Membrane-Bound Pyrophosphatase Inhibitors. 2021

Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), 00014, Helsinki, Finland.

Inhibition of membrane-bound pyrophosphatase (mPPase) with small molecules offer a new approach in the fight against pathogenic protozoan parasites. mPPases are absent in humans, but essential for many protists as they couple pyrophosphate hydrolysis to the active transport of protons or sodium ions across acidocalcisomal membranes. So far, only few nonphosphorus inhibitors have been reported. Here, we explore the chemical space around previous hits using a combination of screening and synthetic medicinal chemistry, identifying compounds with low micromolar inhibitory activities in the Thermotoga maritima mPPase test system. We furthermore provide early structure-activity relationships around a new scaffold having a pyrazolo[1,5-a]pyrimidine core. The most promising pyrazolo[1,5-a]pyrimidine congener was further investigated and found to inhibit Plasmodium falciparum mPPase in membranes as well as the growth of P. falciparum in an ex vivo survival assay.

UI MeSH Term Description Entries
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011755 Pyrophosphatases A group of enzymes within the class EC 3.6.1.- that catalyze the hydrolysis of diphosphate bonds, chiefly in nucleoside di- and triphosphates. They may liberate either a mono- or diphosphate. EC 3.6.1.-. Pyrophosphatase
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
October 2015, Bioorganic & medicinal chemistry,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.
January 2016, Bioorganic & medicinal chemistry letters,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
November 2007, Bioorganic & medicinal chemistry letters,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
December 2009, Bioorganic & medicinal chemistry letters,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors.
December 2009, Bioorganic & medicinal chemistry letters,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Design, synthesis and bioevaluation of 2,7-diaryl-pyrazolo[1,5-a]pyrimidines as tubulin polymerization inhibitors.
October 2021, Bioorganic chemistry,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
November 2018, Bioorganic & medicinal chemistry letters,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
December 2021, Bioorganic chemistry,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Novel pyrazolo[1,5-a]pyrimidines as c-Src kinase inhibitors that reduce IKr channel blockade.
January 2008, Bioorganic & medicinal chemistry,
Niklas G Johansson, and Loïc Dreano, and Keni Vidilaseris, and Ayman Khattab, and Jianing Liu, and Arthur Lasbleiz, and Orquidea Ribeiro, and Alexandros Kiriazis, and Gustav Boije Af Gennäs, and Seppo Meri, and Adrian Goldman, and Jari Yli-Kauhaluoma, and Henri Xhaard
Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2.
February 2005, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!